Drug preparation, injection, and sharing practices in Tajikistan: A qualitative study in Kulob and Khorog

Substance Abuse: Treatment, Prevention, and Policy

Volumn 11, Issue 1, 2016, Pages

  Otiashvili, David ^a   Latypov, Alisher ^b,c   Kirtadze, Irma ^a,d   Ibragimov, Umedjon ^e   Zule, William ^f  

^a Addiction Research Center   (Georgia)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c GEORGE WASHINGTON UNIVERSITY   (United States)

^d ILIA STATE UNIVERSITY   (Georgia)

^e EMORY UNIVERSITY   (United States)

^f RTI INTERNATIONAL   (United States)

Author keywords

Indirect sharing; Infection risks; Injection drug use; Tajikistan

Indexed keywords

ADULT; AGED; ATTITUDE TO HEALTH; DRUG FORMULATION; DRUG USE; HIGH RISK BEHAVIOR; HUMAN; INFORMATION PROCESSING; MALE; MIDDLE AGED; NEEDLE SHARING; PSYCHOLOGY; QUALITATIVE RESEARCH; SUBSTANCE ABUSE; TAJIKISTAN; YOUNG ADULT;

ADULT; AGED; DRUG COMPOUNDING; DRUG USERS; FOCUS GROUPS; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; MALE; MIDDLE AGED; NEEDLE SHARING; QUALITATIVE RESEARCH; RISK-TAKING; SUBSTANCE ABUSE, INTRAVENOUS; TAJIKISTAN; YOUNG ADULT;

EID: 84978976161     PISSN: None     EISSN: 1747597X     Source Type: Journal    
DOI: 10.1186/s13011-016-0065-2     Document Type: Article

References (30)

1. Ancker S, Rechel B. Policy responses to HIV/AIDS in Central Asia. Glob Public Health. 2015;10(7):817-33.
2. DeHovitz J, Uuskula A, El-Bassel N. The HIV epidemic in Eastern Europe and Central Asia. Curr HIV/AIDS Rep. 2014;11(2):168-76.
3. Latypov A, Otiashvili D, Zule W. Drug scene, drug use and drug-related health consequences and responses in Kulob and Khorog, Tajikistan. Int J Drug Policy. 2014;25(6):1204-14.
4. Ministry of Health of Republic of Tajikistan. UNAIDS country progress report. Dushanbe: Ministry of Health of Republic of Tajikistan; 2015.
5. Ministry of Health of Republic of Tajikistan. Report on the results of bio-behavioral surveliance survey among people who inject drugs in Republic of Tajikistan in 2014. 2015.
6. Drug Control Agency under the President of Republic of Tajikistan. Drug situation in the Republic of Tajikistan in 2014. 2015.
7. World Bank. New Country Classifications 2015. Available from: http://data.worldbank.org/news/new-country-classifications-2015. Accessed 15 Aug 2015.
8. Tukeyev M, Ganina L, Yelizarieva A, Petrenko I, Balabayev T, Kudusova E, et al. 2006-2010 Kazakhstan National AIDS Programme Progress Report. Astana: Ministry of Health of the Republic of Kazakhstan. 2011.
9. Ministry of Health of Republic of Tajikistan, UNDP. Modelling an optimised investment approach for Tajikistan. Dushanbe: UNDP; 2014.
10. MacArthur GJ, van Velzen E, Palmateer N, Kimber J, Pharris A, Hope V, et al. Interventions to prevent HIV and Hepatitis C in people who inject drugs: a review of reviews to assess evidence of effectiveness. Int J Drug Policy. 2014;25(1):34-52.
11. Palmateer N, Hutchinson S, McAllister G, Munro A, Cameron S, Goldberg D, et al. Risk of transmission associated with sharing drug injecting paraphernalia: analysis of recent hepatitis C virus (HCV) infection using cross-sectional survey data. J Viral Hepat. 2014;21(1):25-32.
12. Koester S, Glanz J, Baron A. Drug sharing among heroin networks: implications for HIV and hepatitis B and C prevention. AIDS Behav. 2005;9(1):27-39.
13. Rhodes T, Mikhailova L, Sarang A, Lowndes CM, Rylkov A, Khutorskoy M. Situational factors influencing drug injecting, risk reduction and syringe exchange in Togliatti City, Russian Federation: a qualitative study of micro risk environment. Soc Sci Med. 2003;57(1):39-54.
14. Wilkins L, Bissell P, Meier PS. Risky injecting practices associated with snowballing: a qualitative study. Drug Alcohol Rev. 2010;29(3):256-62.
15. Ahmed T, Long TN, Huong PT, Stewart DE. Drug injecting and HIV risk among injecting drug users in Hai Phong, Vietnam: a qualitative analysis. BMC Public Health. 2015;15(1):1-13.
16. Roy E, Arruda N, Bourgois P. The growing popularity of prescription opioid injection in downtown Montreal: new challenges for harm reduction. Subst Use Misuse. 2011;46(9):1142-50.
17. Pouget ER, Hagan H, Des Jarlais DC. Meta-analysis of hepatitis C seroconversion in relation to shared syringes and drug preparation equipment. Addiction (Abingdon, England). 2012;107(6):1057-65.
18. Jackson LA, Bailey DL, Fraser JR, Johnson JK, Currie A, Babineau DD. Safer and unsafe injection drug use and sex practices among injection drug users in Halifax, Nova Scotia. An exploratory look at community and interpersonal influences. Can J Public Health. 2002;93(3):219-22.
19. De P, Roy É, Boivin JF, Cox J, Morissette C. Risk of hepatitis C virus transmission through drug preparation equipment: a systematic and methodological review. J Viral Hepat. 2008;15(4):279-92.
20. Abadie R, Welch-Lazoritz M, Gelpi-Acosta C, Reyes JC, Dombrowski K. Understanding differences in HIV/HCV prevalence according to differentiated risk behaviors in a sample of PWID in rural Puerto Rico. Harm Reduct J. 2016;13:10.
21. Cooper H, Moore L, Gruskin S, Krieger N. The impact of a police drug crackdown on drug injectors' ability to practice harm reduction: a qualitative study. Soc Sci Med. 2005;61(3):673-84.
22. Thanh DC, Moland KM, Fylkesnes K. The context of HIV risk behaviours among HIV-positive injection drug users in Viet Nam: Moving toward effective harm reduction. BMC Public Health. 2009;9:98.
23. Johnson KM, Fibbi M, Langer D, Silva K, Lankenau SE. Prescription drug misuse and risk behaviors among young injection drug users. J Psychoactive Drugs. 2013;45(2):112-21.
24. Grund JP, Friedman SR, Stern LS, Jose B, Neaigus A, Curtis R, et al. Syringe-mediated drug sharing among injecting drug users: patterns, social context and implications for transmission of blood-borne pathogens. Soc Sci Med. 1996;42(5):691-703.
25. WHO, UNODC, UNAIDS. Technical Guide for countries to set targets for universal access to HIV prevention, treatment and care for injecting drug users. 2009.
26. Abdul-Quader AS, Feelemyer J, Modi S, Stein ES, Briceno A, Semaan S, et al. Effectiveness of structural-level needle/syringe programs to reduce HCV and HIV infection among people who inject drugs: a systematic review. AIDS Behav. 2013;17(9):2878-92.
27. Kimber J, Palmateer N, Hutchinson J, Hickman M, Goldberg D, Rhodes T. Harm reduction among injecting drug users - evidence of effectiveness. Harm reduction: evidence, impacts and challenges. Lisbon: European Monitoring Centre for Drugs and Drug Addiction (EMCDDA); 2010. p. 115-63.
28. Turner KME, Hutchinson S, Vickerman P, Hope V, Craine N, Palmateer N, et al. The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence. Addiction. 2011;106(11):1978-88.
29. Jones L, Pickering L, Sumnall H, McVeigh J, Bellis M. A review of the effectiveness and cost-effectiveness of needle and syringe programmes for injecting drug users. Liverpool John Moores University: Centre for Public Health; 2008.
30. McGowan C, Harris M, Rhodes T. Hepatitis C avoidance in injection drug users: a typology of possible protective practices. PLoS One. 2013;8(10):e77038.